
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Overlap of Esophageal Disorders and GERD</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Overlap of Esophageal Disorders and GERD</strong></summary>
            <div>
                <ul><li>Article: Overlap of esophageal disorders of gut-brain interactions (EDGBIs) and GERD is highly prevalent in patients with refractory reflux symptoms.</li><li>Authors: Federico Caldart, Charlotte Gabriel, Blandine Vauquelin, Pauline Rivière, Arthur Berger, Frank Zerbib.</li><li>Journal: American Journal of Gastroenterology.</li><li>DOI: 10.14309/ajg.0000000000003542</li></ul>
                
        <details>
            <summary><strong>Key Concepts</strong></summary>
            <div>
                <ul><li>Focus: Prevalence &amp; characteristics of refractory GERD &amp; E-DGBIs in patients w/ refractory reflux symptoms.</li><li>Key Findings:</li><li>- E-DGBIs are highly prevalent in proven GERD patients w/ refractory symptoms.</li><li>- Prior GERD diagnosis ≠ rule out FH/RH on PPIs.</li></ul>
                
        <details>
            <summary><strong>E-DGBIs</strong></summary>
            <div>
                <ul><li>Esophageal Disorders of Gut-Brain Interaction.</li><li>Includes: Reflux Hypersensitivity (RH) &amp; Functional Heartburn (FH).</li></ul>
                
        <details>
            <summary><strong>Reflux Hypersensitivity (RH)</strong></summary>
            <div>
                <ul><li>Normal AET + Positive symptom-reflux association (SAP &gt;95% and/or SI &gt;50%).</li></ul>
                
        <details>
            <summary><strong>Symptom Association</strong></summary>
            <div>
                <ul><li>Defined by: Symptom Index (SI) &amp; Symptom Association Probability (SAP).</li><li>Positive if: SAP &gt; 95% and/or SI &gt; 50%.</li></ul>
                
        <details>
            <summary><strong>Symptom Index (SI)</strong></summary>
            <div>
                <ul><li>Measure of symptom correlation with reflux events.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Symptom Association Probability (SAP)</strong></summary>
            <div>
                <ul><li>Statistical probability of symptom correlation with reflux events.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Functional Heartburn (FH)</strong></summary>
            <div>
                <ul><li>Normal AET + Negative symptom association (SAP ≤95% and SI ≤50%).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>GERD</strong></summary>
            <div>
                <ul><li>Gastro-Esophageal Reflux Disease.</li><li>Requires: Troublesome symptoms + Evidence of pathological reflux (endoscopy/ambulatory reflux monitoring).</li></ul>
                
        <details>
            <summary><strong>Refractory GERD</strong></summary>
            <div>
                <ul><li>Persistent esophagitis/stricture despite therapy OR Ongoing pathological reflux on pH-impedance monitoring on PPIs.</li></ul>
                
        <details>
            <summary><strong>Actionable GERD</strong></summary>
            <div>
                <ul><li>Ongoing GERD despite PPI therapy.</li><li>Candidates for: Laparoscopic antireflux surgery or magnetic sphincter augmentation.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis of GERD</strong></summary>
            <div>
                <ul><li>Requires compatible troublesome symptoms and evidence of pathological reflux based on endoscopy and/or ambulatory reflux monitoring.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Overlap</strong></summary>
            <div>
                <ul><li>Coexistence of GERD and E-DGBIs.</li><li>Patients may have persistent symptoms related to E-DGBIs despite GERD treatment.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Study Design &amp; Methods</strong></summary>
            <div>
                <ul><li>Prospective data collection from consecutive adult patients w/ typical refractory reflux symptoms.</li><li>Exclusion: Atypical symptoms, prior GI surgery, endoscopically proven refractory GERD.</li><li>Assessment: Endoscopy, manometry, pH/pH-impedance monitoring, questionnaires.</li></ul>
                
        <details>
            <summary><strong>Study Population</strong></summary>
            <div>
                <ul><li>Patients w/ typical symptoms (heartburn, regurgitation, NCCP) referred to Bordeaux University Hospital (Jan 2022 - May 2024).</li><li>Exclusion criteria: Previous GI surgery, primary atypical symptoms, probe misplacement, non-adherence, inability to stop PPIs.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Data Collection</strong></summary>
            <div>
                <ul><li>Age, gender, primary symptoms, pH/pH-impedance data, esophageal motor disorders, endoscopy findings.</li><li>Questionnaires: RDQ, Rome IV (IBS/FD), HADS, VSI.</li></ul>
                
        <details>
            <summary><strong>Reflux Disease Questionnaire (RDQ)</strong></summary>
            <div>
                <ul><li>Assesses reflux symptom burden.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Rome IV Questionnaire</strong></summary>
            <div>
                <ul><li>Identifies IBS &amp; FD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Hospital Anxiety and Depression Scale (HADS)</strong></summary>
            <div>
                <ul><li>Measures anxiety &amp; depression levels.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Visceral Sensitivity Index (VSI)</strong></summary>
            <div>
                <ul><li>Assesses visceral sensitivity.</li><li>Increased VSI: Value &gt; 37.5.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Ambulatory Reflux Monitoring</strong></summary>
            <div>
                <ul><li>Unproven GERD: pH study off PPIs (standard pH catheter/wireless pH capsule).</li><li>Proven GERD: pH-impedance study on twice-daily PPIs.</li></ul>
                
        <details>
            <summary><strong>Lyon 2.0 Criteria</strong></summary>
            <div>
                <ul><li>Used to determine patients’ phenotypes.</li><li>Off PPIs: AET &gt;6% pathological, 4-6% inconclusive, &lt;4% normal.</li><li>Proven GERD: AET &gt;4% or &gt;80 reflux episodes on PPI conclusive for refractory GERD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>MNBI Evaluation</strong></summary>
            <div>
                <ul><li>Evaluated during entire supine period.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Results</strong></summary>
            <div>
                <ul><li>119 patients included (67% female, mean age 49.2 years).</li><li>Unproven GERD (n=73): 23 GERD, 50 E-DGBI (28 RH, 22 FH).</li><li>Proven GERD (n=46): 13 refractory GERD, 33 GERD/E-DGBI overlap (22 FH, 11 RH).</li></ul>
                
        <details>
            <summary><strong>Unproven GERD Group (n=73)</strong></summary>
            <div>
                <ul><li>9 had grade A esophagitis, 64 normal endoscopy.</li><li>After pH study off PPI: 23 GERD, 50 E-DGBI (28 RH, 22 FH).</li><li>14 patients w/ inconclusive AET (4-6%) included in E-DGBI group based on SAP &amp; SI.</li><li>26 &amp; 8 patients had anxiety &amp; depression scores above 8.</li><li>16 (21.9%) patients had VSI &gt; 37.5.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Proven GERD Group (n=46)</strong></summary>
            <div>
                <ul><li>25 had normal endoscopy, 4 grade A, 16 grade B/C esophagitis, 1 Barrett’s.</li><li>13 (28%) confirmed refractory GERD (7 ↑AET, 6 &gt;80 reflux episodes).</li><li>33 (72%) no evidence of pathological GERD on PPIs -&gt; GERD/E-DGBI overlap (22 FH, 11 RH).</li><li>13 &amp; 6 patients had anxiety &amp; depression scores above 8.</li><li>10 (21.7%) patients had VSI &gt; 37.5.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Prevalence of FD &amp; IBS</strong></summary>
            <div>
                <ul><li>High prevalence of FD (70.6%) &amp; IBS (33.6%) symptoms reported.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>E-DGBI Patients Comparison</strong></summary>
            <div>
                <ul><li>Compared E-DGBI alone (n=50) vs. GERD overlap (n=33).</li><li>No significant differences: gender, age, MNBI, RDQ, HADS, VSI, IBS, FD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>RH Patients Comparison</strong></summary>
            <div>
                <ul><li>Compared RH alone (n=28) vs. GERD overlap (n=11).</li><li>No significant differences: gender, age, HADS, RDQ, IBS, FD.</li><li>↑ Visceral sensitivity (VSI) in GERD overlap group (p=0.033).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>FH Patients Comparison</strong></summary>
            <div>
                <ul><li>Compared FH alone (n=22) vs. GERD overlap (n=22).</li><li>No significant differences: MNBI, RDQ, HADS, VSI, IBS, FD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Refractory GERD vs. Overlap Comparison</strong></summary>
            <div>
                <ul><li>Compared refractory GERD (n=13) vs. GERD-E-DGBI overlap (n=33).</li><li>Refractory GERD: ↑ AET (p=0.016), ↓ MNBI (p=0.006), ↑ reflux episodes (p&lt;0.001).</li><li>RDQ higher in refractory GERD (p=0.085, not significant).</li><li>No significant differences: HADS, VSI, IBS, FD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Discussion</strong></summary>
            <div>
                <ul><li>E-DGBIs are main cause of PPI failure in proven GERD (72%).</li><li>Prior GERD diagnosis ≠ rule out FH/RH on PPIs.</li><li>Only 10.9% had refractory GERD after investigations.</li><li>High prevalence of non-esophageal DGBI conditions (IBS, FD).</li></ul>
                
        <details>
            <summary><strong>E-DGBI Prevalence</strong></summary>
            <div>
                <ul><li>E-DGBIs present in up to 40% of patients w/ refractory reflux-like symptoms treated empirically w/ PPIs.</li><li>Present study: E-DGBIs are main cause of PPI failure in proven GERD (72%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Actionable GERD</strong></summary>
            <div>
                <ul><li>In present study, among 46 patients with proven GERD studied with pH-impedance monitoring on PPIs, only 13 (28.2%) had pathological reflux, 11 (23.9%) had reflux hypersensitivity, and 22 (47.8%) had functional heartburn.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Overlap Similarity</strong></summary>
            <div>
                <ul><li>Patients w/ overlapping GERD &amp; E-DGBIs had similar symptom scores &amp; psychometric profiles to patients w/ E-DGBIs alone.</li><li>Both groups likely share similar underlying mechanisms (altered autonomic activity, ↑ nociceptor sensitivity, altered central processing).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Psychological Factors</strong></summary>
            <div>
                <ul><li>Psychological factors significantly impact symptom severity more than physiological parameters in refractory reflux symptoms.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Limitations</strong></summary>
            <div>
                <ul><li>Retrospective design, no treatment outcome data, adherence to PPI therapy not checked for all patients with unproven GERD, tertiary care center, low number of patients with truly refractory GERD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusion</strong></summary>
            <div>
                <ul><li>E-DGBIs are highly prevalent in proven GERD patients w/ refractory symptoms despite PPIs.</li><li>Patients w/ E-DGBIs &amp; proven GERD have similar clinical &amp; psychometric profiles to patients w/ E-DGBI w/o GERD.</li><li>Outcome data needed to determine if these patients should be identified using pH-impedance monitoring on PPIs before interventional treatment.</li></ul>
                
        <details>
            <summary><strong>Future Research</strong></summary>
            <div>
                <ul><li>Should investigate long-term trajectories of GERD-EDGBI overlap patients and evaluate responses to neuromodulators and dietary interventions.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
